Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Time to Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $52.6840, but opened at $49.0692. Zealand Pharma A/S shares last traded at $49.0692, with a volume of 100 shares traded.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ZLDPF shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. Zacks Research lowered Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 13th. Jefferies Financial Group downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Berenberg Bank lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Zealand Pharma A/S currently has a consensus rating of “Hold”.

Zealand Pharma A/S Price Performance

The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02. The company has a fifty day simple moving average of $46.03 and a 200 day simple moving average of $49.09. The firm has a market capitalization of $3.51 billion, a P/E ratio of 8.14 and a beta of 0.88.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.